NCT05686759
A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.
A Phase 3b Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. in Post-liver Transplant Patients
GC Biopharma Corp·Phase 3·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Hepatitis B
- Drug/Device/Intervention
- Undiluted I.V.-Hepabig inj(GC5103)
- Study type
- Interventional
- Intervention type
- biological
Sponsor & location
- Primary sponsor
- GC Biopharma Corp
- Location
- Seoul, South Korea
Timeline & enrollment
- Phase
- Phase 3
- Start date
- Jan 18, 2023
- End date
- Sep 01, 2025
- Enrollment
- 200 participants
Primary outcome
Adverse events occurred during clinical trials
Summary
The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous
 infusion of I.V.-Hepabig inj. in post-liver transplant patients
ICD-10 classifications
Acute hepatitis BAcute hepatitis B without delta-agent and without hepatic comaAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agentChronic viral hepatitis B without delta-agent : other and unspecified phase
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05686759
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05686759 through Pure Global AI's free database. This Phase 3 trial is sponsored by GC Biopharma Corp and is currently Recruiting. The study focuses on Hepatitis B. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.